- 1 **Category:** Original Article
- 2 **Title:** Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with
- 3 hydroxychloroquine and azithromycin in Lebanon.
- 5 Authors:

9

22

- 6 Amanda Chamieh^{1,2}, Claude Afif², Gerard El-Haji³, Omar Zmerli², Isabelle Djaffar-
- 7 Jureidini⁴, Roy A. Raad³, Raja Ashou³, Georges Juvelekian⁵, Jean-Marc Rolain¹ and Eid
- 8 Azar^{2*}
- 10 **Affiliations:**
- 11 1- Aix-Marseille Université, AP-HM, Institut de Recherche pour le Développement
- 12 (IRD), Microbes Evolution Phylogeny and Infections (MEPHI), Institut Hospitalo-
- Universitaire Méditerranée-Infection, Marseille, France.
- 2- Division of Infectious Diseases, Saint George Hospital University Medical Center,
- 15 Beirut, Lebanon.
- 16 3- Department of Radiology, Saint George Hospital University Medical Center, Beirut,
- 17 Lebanon.
- 4- Department of Laboratory Medicine, Saint George Hospital University Medical
- 19 Center, Beirut, Lebanon.
- 20 5- Department of Pulmonary and Critical Care Medicine, Saint George Hospital
- 21 University Medical Center, Beirut, Lebanon.
- 23 **Running Title:** Viral Dynamics Matter in COVID-19 Pneumonia
- 25 Declarations of Interest and Funding/Support Statement:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements:

This work was supported by the Saint George Hospital University Medical Center Beirut, Lebanon.

*Corresponding Author:

Eid Azar, M.D.

Infectious Disease, Chief of Staff

Associate Chief Medical Officer for Safety, Risk Management, and Infection Prevention and Control

Saint George Hospital University Medical Center, Youssef Sursock St. – Achrafieh, Beirut, Lebanon; eeazar@stgeorgehospital.org; +961 03 665358

Category: Original Article

- **Title:** Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with
- 44 hydroxychloroquine and azithromycin in Lebanon.
- **Running Title:** Viral Dynamics Matter in COVID-19 Pneumonia

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

1. Abstract 1.1. Background/Purpose We share our experience in COVID-19 pneumonia management at Saint George Hospital University Medical Center (SGHUMC) in Lebanon. In the absence of a standard of care, early diagnosis and opt-in therapy with Hydroxychloroquine and Azithromycin were offered. 1.2. Methods We reviewed records of COVID-19 pneumonia patients from March 16-April 26 2020. Based on NEWS score, we stratified patients as A: low B: medium, and C: high clinical severity and obtained pharmacotherapy data. Chest-CT-severity-score (CTSS) was used. We defined clinical cure as resolution of symptoms and biomarkers and virologic cure as a PCR above 35 cycles(Ct). 1.3. Results We recorded 21 COVID-19 pneumonia patients of whom 19 opted for treatment. Clinical symptoms and laboratory markers at presentation did not significantly correlate with severity. Lower initial viral load significantly correlated with lower levels of clinical and radiological severity (p=0.038). Virologic cure, Ct>35, by day 10, was only 33% in high severity significantly less than categories A and B. We observed 100% clinical cure at day 10 in Category-A, 67% in B, and 33% in C(p<0.05). Patients with the lowest severity had the fastest virologic cure in a mean of 5.8 days from diagnosis, shortest hospitalization and earlier radiological improvement(p<0.005). Ultimately, 18 patients were discharged home in good condition and one remains in the ICU. 1.4. Conclusion: Viral dynamics matter in COVID-19 pneumonia. An early control of replication may be crucial in averting complications. Early administration of Hydroxychloroquine and

- Azithromycin potentially explains our 94.7% success rate in treating a fairly complex cohort
- 72 of COVID-19 pneumonia.
- 74 Keywords:

- 75 COVID-19 pneumonia
- 76 Viral Load Dynamics in SARS-CoV-2
- 77 Hydroxychloroquine and Azithromycin in COVID-19

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

2. Introduction SARS-CoV-2 is a novel coronavirus that is taking the world as we know it by storm. In Lebanon, on February 21 2020, SARS-CoV-2 was first diagnosed in a female returning from the epicenter in Iran. Subsequently, the Lebanese government closed early on schools and enterprises, banned gatherings, and advised social distancing and home quarantine. Until April 26 2020, Lebanon is at 704 cases in a country of an estimated 6.7 million inhabitants.¹ Globally, the approaches to managing COVID-19 pandemic are diverse. One method advocates conservative, home-stay for mild cases while reserving diagnostics and medical intervention for severe cases. Another main strategy is almost opposite and relies on early diagnosis by offering RT-PCR testing^{2,3}. At Saint George Hospital University Medical Center (SGHUMC) in Lebanon, we formed the SGHUMC COVID-19 response team and carefully reviewed existing evidence and management strategies. We opted for an early detection approach. We tested all incoming patients with an acute respiratory, febrile illness or known exposure for SARS-CoV-2 by RT-PCR, traced their contacts, and performed prompt chest CT scan imaging as indicated. In the absence of a standard of treatment for COVID-19, we assessed available therapies. Hydroxychloroquine and azithromycin are readily available promising combination with a familiar pharmacologic profile. On the other hand, lopinavir/ritonavir lacks significant clinical benefits and remdesivir use is restricted to clinical trials or compassionate use. These two options above are not available in Lebanon. IL-6 pathway inhibitors and convalescent plasma treatment are in trial reserved for advanced COVID-19. Therefore, we agreed to consider them on a case-by-case basis.⁴⁻⁹

In summary, patients with COVID-19 pneumonia chose either no pharmacological treatment or the combination of Hydroxychloroquine and azithromycin. Patients opting for the Hydroxychloroquine and azithromycin regimen consented verbally after having the risks and potential benefits of this regimen well explained to them.

In this retrospective study, we share our experience with COVID-19 pneumonia clinical and radiological presentations and outcomes, course of illness, and viral dynamics.

110 3. Methods 111 3.1. Study setting and Design 112 We conducted this retrospective study at SGHUMC in Beirut, Lebanon, from 113 March 16, 2020 until April 26, 2020. 114 Patients were received via our Emergency Room and Corona Clinic or as 115 transferals requiring urgent critical care, some of which were COVID-19 confirmed. 116 We obtained exposure and contact history of all incoming patients with 117 respiratory or febrile illnesses and performed a physical exam. Nasopharyngeal and 118 oropharyngeal swabs were obtained for SARS-CoV-2 RT-qPCR. Chest CT imaging was 119 done within 3 days of diagnosis. 120 The SGHUMC response team was composed of infectious disease physicians, 121 pulmonary and critical care physicians, radiologists, infection preventionists, nursing 122 department, laboratory department, and a representative from hospital leadership. 123 Clinical and virologic cure was assessed at day 10 from diagnosis. Patients were 124 followed until complete clinical and virologic clearance, defined as the overall outcome. 125 3.2. Inclusion Criteria 126 In our analysis, we included all patients that were positive for SARS-CoV-2 127 by RT-qPCR with findings of pneumonia on chest CT scan and had received 128 Hydroxychloroquine and azithromycin for at least 72 hours. 129 3.3. Data Collection 130 We retrieved data from the electronic database of the COVID-19 clinic and emergency care service. We recorded patient age, gender, history of cardiovascular 131 132 disease, hypertension, chronic lung conditions, diabetes mellitus, malignancy, and any 133 immunosuppressive therapy. We also recorded possible exposure history and

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

reported symptoms of cough, fever, headache, shortness of breath, chills, myalgias, sore throat, rhinorrhea, and diarrhea. The time from symptom onset to diagnosis, imaging and treatment initiation, length of hospital stays, the need for oxygenation, and whether the patient was transferred to the intensive care unit (ICU) were retrieved. Laboratory markers included CBC, Creatinine, CRP, Troponin, Procalcitonin, Urea, Na, K, Ca, Mg, AST, ALT, Bilirubin, LDH, D-Dimer, Ferritin, and Fibrinogen depending on the case. We considered day zero as the day of diagnosis of COVID-19 by RT-qPCR. At day 10, patients were assessed for clinical and virologic cure. Some patients underwent a repeat chest CT scan. 3.4. Clinical Assessment: We used the National Early Warning Score (NEWS) and chest CT scan findings to assess acute clinical severity on admission. ¹⁰ The NEWS is based on physiologic parameters that include respiratory and heart rate, blood pressure, oxygen saturation, use of supplemental oxygen, and state of consciousness. A NEWS score of 0-4, 5-6, and 7-15 respectively corresponded to low, medium, and high scores. For the sake of data analysis, we then divided our cohort into categories A, B, and C according to low, medium, and high NEWS score. We define clinical cure as the resolution of symptoms, clinical stabilization, and normalization of inflammatory markers. Patients were managed as inpatients or followed as outpatients depending on their clinical severity. Outpatients were discharged with strict instructions and education, and were called for follow up every 2 days. 3.5. PCR Assay

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

RNA was extracted from nasopharyngeal/oropharyngeal samples. Real-time reverse transcriptase PCR (RT-qPCR) detection of SARS-CoV-2 was done using the LightMix® ☐ Modular SARS-CoV-2 (COVID19) E, N, and RdRP-genes (Tib Molbiol, Berlin, Germany) as previously described. 11,12 We used the cycle number threshold values (Ct) as an indicator of the number of copies of SARS-CoV-2 present in our samples. We define virologic cure as 2 consecutive SARS-CoV-2 RT-qPCR with Ct>35, as previously described.¹³ We considered a patient with virologic cure by day 10 of diagnosis a fast responder and a slow responder if more than 10 days. All patients were followed with serial RT-PCR till negative, beyond limit of detection of the test, as part of SGHUMC infection control strategy. We also tested for other pathogens using Biofire® FilmArray® Respiratoy 2 Panel (BioMerieux, France) following manufacturer's instructions. 3.6. Radiologic Assessment: Non-enhanced low-dose chest CT scans were obtained in supine position on a "GE Healthcare: Discovery CT750 HD" CT scanner, dedicated for confirmed or suspected COVID-19 patients. Patients were instructed to hold their breath, and acquisition was made at end-inspiration. COVID-19 typical findings were recorded, including: (a) ground-glass opacities, (b) dense airspace consolidation, (c) interlobular septal thickening, (d) vascular enlargement, (e) peripheral, subpleural distribution, and (f) multifocal/multilobar/bilateral involvement. The presence of pleural effusion and other findings atypical for pneumonia was also assessed. Chest CT severity score (CTSS) was determined to estimate the severity of lung involvement in patients with COVID-19 pneumonia. The scoring system was adapted from similar scoring systems

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

used in recent COVID-19 literature. ^{14,15} A score of 0, 1, 2, or 3 (corresponding to involvement of 0%, 0-25%, 25-50%, and >50% respectively) was assigned for each lobe of the 5 lung lobes with a maximum total score of 15. Therefore, if a patient has a CTSS of 15, it indicates that there is more than 50% involvement of the lung. Interval improvement and resolution is a decrease in CTSS and/or subjective decrease in ground-glass opacities density. All images were anonymized then analyzed by two experienced radiologists (R.A. and R.R.) independently. In case of discrepant CT findings or CTSS, a final decision was reached by consensus. 3.7. Treatment: 3.7.1. Pharmacologic therapy for patients receiving Hydroxychloroquine and azithromycin We verified for any drug-drug interactions, G6PD deficiency and contraindications, and we obtained an ECG. If QTc<460msec, treatment was initiated. ¹⁶ When QTcB>460msec, we consulted a cardiologist that ordered continuous cardiac monitoring by telemetry if needed. ECG was repeated on day 2 and day 10 upon completion of therapy. We administered 600mg of Hydroxychloroquine per os per day for 10 days and a 500mg loading dose of azithromycin followed by 250mg/day for 4 days intravenously or orally. 3.7.2. Non-pharmacologic Treatment: Supportive and symptomatic therapy, such as oxygen, was assessed individually. 3.8. Statistics The Shapiro-Wilk test was used to assess normality. Data were expressed as mean \pm SD and/or median [minimum; maximum]. The nonparametric Man-

Whitney U or Kruskal-Wallis H test was applied to assess for differences between categories. The Wilcoxon signed-rank test was used to assess improvement in CTSS values on follow-up CT. A Spearman's rank-order correlation was used for interrater reliability between the radiologists' CTSS. The rank-based Jonckheere-Terpstra test was applied to trend the 3 clinical severity groups and cycle threshold numbers. P-values<0.050 were significant.

3.9. Ethical Statement:

We obtained SGHUMC IRB approval for a retrospective review of the charts of COVID-19 patients. It is standard procedure that all patients sign a general informed consent for receiving medical acts and care.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

4. Results Out of 860 patients that presented to our COVID-19 clinic, 27 patients had SARS-CoV-2 RT-PCR positive nasopharyngeal swabs at our institution. Six of the 27 patients were asymptomatic with a normal chest CT scan. Two of the remaining 21 patients with COVID-19 typical pneumonia features on chest CT scan refused pharmacologic treatment and followed-up with their physicians. These 8 patients were excluded. Finally, 19 patients were included, all opting for treatment with the combination of Hydroxychloroquine and azithromycin. To note, two patients, not diagnosed nor initially treated at SGHUMC, were transferred to SGHUMC for critical care. Both had advanced COVID-19 and died within 72 hours of admission. These two patients were excluded. The mean age in our study cohort was 57.8±16.4 years. Category A of low clinical severity was composed of 4 males and 6 females, with a median age of 51[28;85]. Category B was composed of 5 males and 1 female, median age 59[52;67]. Category C was composed of 2 males and 1 female, median 81[55;87]. No statistical difference observed in ages across the 3 categories. We observed a higher ratio of 11 males to 8 females. As for comorbidities, 4 patients in category A had hypertension (HTN) and another 4 had dyslipidemia. In category B, one patient was a smoker with mild chronic bronchitis, and another one had coronary artery disease (CAD), HTN, and dyslipidemia. In category C, one patient had CAD, HTN and dyslipidemia while another was a smoker. None of the patients were known diabetics. Only 1 patient with COVID-19 pneumonia of medium NEWS score was co-infected with RSV. 4.1. Clinical Course and Cure

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

The median duration from initial symptom onset to diagnosis of COVID-19 was 3.5[1;18] days in category A, 8[2;12] days in category B and 4[2;8] days in category C. This was not statistically significant. At initial evaluation, there was no significant variation between symptoms reported by patients. They reported fever in 15/19, cough in 13/19, shortness of breath in 9/19, myalgias in 5/19, sore throat in 4/19, chills in 2/19, headache in 2/19, and 1/19 with fatigue. Anosmia was reported by 1 patient. We also found no significant difference in laboratory markers among patients of all categories upon presentation. 4.1.1. Clinical Course The length of stay of patients in category A was a mean of 3±4.8 days, median 1[0;12] days, significantly lower than both category B at a mean of 11±4.8 days; median 12.5[3,16] days (p=0.032) and category C at a mean of 20±8.5 days, median of 19[12,29] days(p=0.015). No statistical significance in LOS between medium and high clinical severity. There was no distinct pattern for progression of laboratory markers. However, when peak values are reached, it took 4-6 days to return to baseline. This was independent of initial clinical severity. Table 1 represents the results of available blood tests during the study period per category. On average, category A of low clinical severity had an overall significantly lower CRP, Procalcitonin, LDH, Ferritin, D-Dimer, and lymphopenia. 4.1.2. Clinical Cure at day 10: All patients in category A achieved clinical cure on day 10 compared to 4/6 in category B. In category C, only 1 patient achieved clinical cure at day 10. Thus, 100% clinical cure at day 10 in low clinical severity, 67% in medium severity, and 33% in high severity COVID-19. This trend was statistically significant (p=0.031).

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

4.1.3. Overall Clinical Outcome Eighteen out of 19 patients were discharged home in good condition, a clinical success rate of 94.7%. Only 1 patient in category C was still on mechanical ventilation. This patient is the eldest in the cohort at 87 years and had the highest NEWS score of 9 on admission. None of the patients developed any drug related adverse events. 4.2. Virologic Load Dynamics 4.2.1. Initial Viral Load: A higher initial SARS-CoV-2 RT-PCR Ct reflects a lower viral load. There was a statistically significant trend of higher Ct value with lower levels of clinical severity (p=0.038). Median Ct in category A was 33.5(13,38) which is significantly lower than that of category B at Ct= 30[23,35]. This was also significantly lower than the initial Ct in category C of 24[13,29] (Figure 1A). 4.2.2. Virologic Outcome at Day 10 In category A, PCR results were available for only 8/10 patients, and 6/8 patients achieved virologic cure at day 10 in a mean of 5.8±4.2 days. In category B, PCR results were available for 5/6 patients, and 4 achieved virologic cure in a mean of 9.2±4.2 days. In category C, only 1/3 patients achieved virologic cure in 4 days. (Figure 2) 4.2.3. Overall Virologic Cure At the end of the study, SARS-CoV-2 RT-PCR results were available for all patients. In category A, eight of ten patients achieved virologic cure, beyond the limit of detection of our test at mean of 14.8±7.7 days. In category B, all patients achieved virologic cure beyond limit of detection of our test and clinical cure at a mean of

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

16±5 days. As for category C, only 2 out of the 3 patients achieved virologic cure beyond limit of detection of our test on days 21 and 24. (Figure 2) Patients with lower clinical severity reached virologic cure significantly faster than those of higher severity (p=0.042). 4.3. Radiologic Findings: There was a strong, positive correlation between the two readers R.A. and R.R., which was statistically significant (rs(36) = 0.958, p < 0.001). All patients had a chest CT scan done within 3 days of COVID-19 diagnosis. To note, the median time from symptom onset to imaging was 3 days for categories A and C and 8 days for category B. (p = 0.842). On initial CT, there was a statistically significant difference in chest CT Severity Score(CTSS) between the 3 categories (p = 0.012) (Figure 1B). Patients of category B showed the highest median CTSS of 10/15 compared to A and C (4/15 (p = 0.003) and 6/15 (p = 0.192), respectively). (Figures 3,4). Only 15 patients underwent follow-up chest CT scans at a median of 14 days (range 10-26 days). Thirteen (87%) patients showed significant interval improvement of which two patients showed complete resolution (p = 0.031). (Figure 5) The remaining two patients with worsening features on second CT showed significant improvement on the subsequent third CT scan (Figure 6), obtained on day 20 and 29 respectively. The median follow-up interval from time of diagnosis to radiological improvement for the 15 patients was: 14 (10-24), 12 (10-29), and 20 (14-26) days for categories A, B, and C respectively.

5. Discussion

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

At SGHUMC, 78% of patients diagnosed with COVID-19 had pneumonia on chest CT scan. Symptoms such as shortness of breath and dyspnea were not reliably predictive of disease severity. Our low threshold to perform chest CT scan was crucial in early diagnosis. In our cohort, an initially low viral load was associated with less severe clinical and radiological findings, and faster viral clearance. All patients in category A achieved clinical cure in 10 days and had the fastest virologic cure in a mean 5.8 days from diagnosis. In contrast, only 56% of patients of higher clinical severity achieved clinical cure in 10 days, had longer hospital stays, and a more prolonged viral shedding. A recent study on 1061 patients with COVID-19 at IHU-Mediterranee Infection in Marseille, France showed that patients with higher initial viral load were less likely to have a low clinical severity and more likely to have poor virologic outcome. ¹⁷Our results are consistent with their findings confirming that initial viral load and kinetics of viral clearance matter in COVID-19. In many viral infections, early control of viral replication is crucial for better outcomes. Hydroxychloroquine has an antiviral effect that is proven in-vitro and in-vivo. ¹⁸⁻²³ We had a 94.7% success rate in treating a fairly complex cohort of COVID-19 pneumonia, with 18/19 patients discharged at baseline conditions. None of our 19 pneumonia patients had a cytokine storm, and all had a rapid decline within 4 days from peak inflammatory laboratory markers. The latter is likely a result of virologic control and possible early attenuation of cytokine storm. 7,24,25 Chest CT scan is a helpful diagnostic tool but also serves to monitor progression. Thirteen of 15 follow-up chest CT scans improved within 14 days. The remaining two showed improvement in a third scan beyond 20 days. In fact, all patients improved, showing either complete resolution or marked improvement in the CT findings, mainly ground-glass opacities and parenchymal consolidations. A follow-up chest CT may be necessary in

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

patients with COVID-19 to monitor for secondary organizing pneumonia and subsequent fibrosis, similar to outcomes seen with SARS and MERS.¹⁴ We will continue to monitor our patients for such complications despite the current significant radiologic improvement. Our observational retrospective cohort is not designed to measure the direct impact of hydroxychloroguine and azithromycin treatment on the outcome of COVID-19 pneumonia. However, in 10 days, 80% of patients with varying severity of pneumonia reached clinical cure, and 70% achieved a virologic cure. Hence, early diagnosis of COVID-19 pneumonia coupled with administering Hydroxychloroquine and azithromycin treatment contributed to faster clinical and radiologic resolution and virologic clearance, potentially averting complications. In conclusion, it is clear that higher viral load and prolonged viral shedding results in a longer and more complex clinical course. Our experience in early patient tracing, testing, chest imaging, and treatment of COVID-19 of mild, moderate, and severe pneumonia with Hydroxychloroquine and azithromycin resulted in a 95% success rate with no mortality. Further studies outside of a pandemic setting are needed to fully and fairly demonstrate the impact of early treatment of COVID-19 pneumonia with Hydroxychloroquine and azithromycin on overall patient outcome, long-term lung damage and reduction of the transmission of SARS-CoV-2.

359 6. References 360 1. Coronavirus disease 2019 [Internet]. [cited 2020 Apr 21]. Available from: 361 https://www.who.int/emergencies/diseases/novel-coronavirus-2019 362 2. Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, et al. Rapid 363 viral diagnosis and ambulatory management of suspected COVID-19 cases presenting 364 at the infectious diseases referral hospital in Marseille, France, - January 31st to March 365 1st, 2020: A respiratory virus snapshot. Travel Med Infect Dis. 2020 Mar;101632. 366 3. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier 367 Transmission of COVID-19. Vol. 323, JAMA - Journal of the American Medical 368 Association. American Medical Association; 2020. p. 1406–7. 369 4. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for 370 Coronavirus Disease 2019 (COVID-19): A Review. Jama [Internet]. 2020;2019. 371 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32282022 372 5. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and 373 treatment of COVID-19. Int J Antimicrob Agents [Internet]. 2020;(xxxx):105955. 374 Available from: https://doi.org/10.1016/j.ijantimicag.2020.105955 375 6. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and 376 hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 377 [Internet]. 2020;105932. Available from: 378 http://www.ncbi.nlm.nih.gov/pubmed/32145363 379 7. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. 380 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an 381 open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 382 8. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir

in Adults Hospitalized with Severe Covid-19. N Engl J Med [Internet]. 2020 Mar 18

384 [cited 2020 Apr 29]; NEJMoa2001282. Available from: 385 http://www.nejm.org/doi/10.1056/NEJMoa2001282 386 9. Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19) 387 based on current evidence. Int J Antimicrob Agents [Internet]. 2020;105948. Available 388 from: https://doi.org/10.1016/j.ijantimicag.2020.105948 389 10. Royal College of Physicians. National Early Warning Score (NEWS) 2. Standardising 390 the assessment of acute-illness severity in the NHS Updated report of a working party 391 Executive summary and recommendations. 2017;(December):1–15. Available from: 392 www.rcplondon.ac.uk 393 11. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection 394 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 395 2020;25(3). 396 12. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative RT-397 PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high 398 throughput system. Euro Surveill. 2020;25(9):1–5. 399 La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral 13. 400 RNA load as determined by cell culture as a management tool for discharge of SARS-401 CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis Off 402 Publ Eur Soc Clin Microbiol. 2020;20–2. 403 14. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT 404 Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology 405 [Internet]. 2020 Mar 19 [cited 2020 May 9];200843. Available from: 406 http://pubs.rsna.org/doi/10.1148/radiol.2020200843 407 15. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On 408 Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia.

409 Radiology. 2020 Feb 13;200370. 410 16. Hache G, Marc Rolain J, Gautret P, Deharo J-C, Brouqui P, Raoult D, et al. 411 Combination of hydroxychloroquine plus azithromycin as potential treatment for 412 COVID 19 patients: pharmacology, safety profile, drug interactions and management 413 of toxicity. 414 17. Million M, Lagier J, Gautret P, Colson P, Fournier E, Amrane S, et al. Early treatment 415 of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective 416 analysis of 1061 cases in Marseille, France. Travel Med Infect Dis [Internet]. 417 2020;101738. Available from: https://doi.org/10.1016/j.tmaid.2020.101738 418 18. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to 419 face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 420 2007;30(4):297–308. 421 19. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and 422 Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of 423 Severe Acute Respiratory Syndrome Main point□: Hydroxychloroquine was found to 424 be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis. 425 2020;2:1–25. 426 20. Weston S, Haupt R, Logue J, Matthews K, Frieman MB. FDA approved drugs with 427 broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. 2020;(3). 428 21. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of 429 chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob 430 Agents [Internet]. 2020;(December 2019):105938. Available from: 431 https://doi.org/10.1016/j.ijantimicag.2020.105938 432 22. Viveiros Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19

treatment. 2020;1–7. Available from: https://doi.org/10.26633/RPSP.2020.40

441

23. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro 435 testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows 436 synergistic effect. Microb Pathog. 2020 Aug 1;145:104228. 437 24. Ashraf MA, Shokouhi N, Shirali E, Davari-tanha F, Memar O, Kamalipour A, et al. 438 COVID-19 in Iran, a comprehensive investigation from exposure to treatment 439 outcomes. medRxiv [Internet]. 2020 [cited 2020 May 9];2020.04.20.20072421. 440 Available from: http://medrxiv.org/content/early/2020/04/24/2020.04.20.20072421.abstract 442 25. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in 443 patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 444 2020;2020.04.10.20060558. 445 446

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470


471


7. Table/Figure Legends 7.1. Table 1: Laboratory Markers of Patients in Category A, B, and C of low, medium and high clinical severity 7.2. Figure 1: (A) Initial viral load: A higher initial SARS-CoV-2 RT-PCR cycle threshold number (Ct) reflects a lower viral load. There was a statistically significant trend of higher Ct value with lower levels of clinical severity (p=0.038). (B) Initial Chest CT Severity Score (CTSS): On initial CT, there was a statistically significant difference in CTSS between the 3 categories (p = 0.012). Patients of category B of medium clinical severity had higher CTSS than category A (low clinical severity) (p = 0.003) and category C (high clinical severity) (p = 0.192). 7.3. Figure 2: Viral Dynamics from day of diagnosis till negativity. x-axis: Days since diagnosis of COVID-19 pneumonia. y-axis: SARS-CoV-2 RT-PCR cycle threshold number (Ct) follow up according to low(A), medium(B), and high(C) clinical severity. Patients with lower clinical severity reached virologic cure significantly faster than those of higher severity (p=0.042). 7.4. Figure 3: Axial serial chest CT images of a 66-year-old female with cough, fever, and shortness of breath (category A). Baseline chest CT demonstrating multilobar ground-glass opacities and dense consolidations predominantly in a peripheral subpleural distribution, with associated interlobular septal thickening ("crazy paving pattern") and vascular enlargement sign (arrows). Chest CT Severity Score was estimated at 9/15. Clinically cured at day 10, and virologic cure confirmed after 21 days. 7.5. Figure 4: Axial serial chest CT images of a 59-year-old female (category B) with cough, fever, shortness of breath. Baseline chest CT demonstrating multilobar ground-glass opacities and dense consolidations predominantly in a peripheral

subpleural distribution, with associated mild septal thickening. Chest CT Severity
Score was estimated at 12/15.

7.6. Figure 5: Three patients with COVID-19 pneumonia findings including peripheral subpleural ground glass opacities and dense consolidations in the lower lobes (A and C) and in the right lower lobe (B), with near-complete resolution on follow-up CTs (D,F and G). Chest CT Severity Score also improved on follow-up exams.

7.7. Figure 6: Chest CT of a 29-year-old female with fever, myalgia, and possible contact with COVID-19 positive case. Baseline chest CT (Day 1) showing a solitary rounded mixed attenuation opacity in the right lower lobe. Findings worsened on the initial follow-up chest CT (Day 12), with multiple new ground-glass opacities in the right lower lobe (B), then completely resolved on the subsequent follow-up CT (Day 29).





Days since diagnosis of COVID-19 pneumonia

